New Drug Approvals

Home » Phase3 drugs » New oral anticancer drug, TS-1 (S-1)

New oral anticancer drug, TS-1 (S-1)



Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 


Recent Posts

Blog Stats

  • 3,942,587 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,726 other followers

add to any


New oral anticancer drug, TS-1 (S-1)

novel oral anticancer agent, S-1, as a combination drug with a molar ratio of 1:0.4:1 for FT, CDHP, and Oxo, respectively

components, an oral fluoropyrimidine agent, tegafur (FT);

a DPD inhibitor (CDHP: 5-chloro-2, 4-dihydroxypyridine) which is about 200-fold more potent than uracil used in UFT;


an ORTC inhibitor (Oxo: potassium oxonate) which is localized in the gastrointestinal tract

TS-1 and (TS-), the gastric cancer (oral anti-cancer agent that is used, for example, an anti-cancer agent is a kind of), is classified as an antimetabolite.

Product names, TS- , the common name tegafur, gimeracil, oteracil potassium in, manufacturing, vendors are Taiho Pharmaceutical Co., Ltd

Tegafur (tegafur, international generic name ) is a cancer to thechemotherapy used in the fluorouracil of prodrug is. Tegafur-uracil ( UFTcomponents of). Tegafur is metabolized fluorouracil shows anti-cancer activity

5-fluoro-1-(tetrahydrofuran-2-yl) pyrimidine-2, four (1 H , three H )-dione

Wednesday, 30 January 2013

ASCO GU – Another Breakthrough in Pancreatic Cancer – TS-1 superior to Gemcitabine in improving overall survival in patients with resected Pancreatic Cancer

Taiho Pharmaceutical Co., Ltd.  announced results of a Randomized phase III trial of adjuvant chemotherapy with gemcitabine (GEM) versus S-1(TS-1) for patients with resected pancreatic cancer (JASPAC-01*1) (Abstract No. 145) at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology.
The primary endpoint of the trial was to gauge non-inferiority of TS-1 to gemcitabine, however an interim analysis of survival data suggests that TS-1 is infact superior to Gemcitabine. As a result, the independent data monitoring committee has recommended  to publish the results soon.  
The HR for S-1 to GEM was 0.56 (95% CI, 0.42-0.74, p<0.0001 for non-inferiority, p<0.0001 for superiority). The 2-year survival rates were 53% (95% CI, 46-60) for GEM and 70% (63-76) for S-1.
This was the first Phase III clinical trial indicating the effectiveness of TS-1 in patients with resected pancreatic cancer.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Follow New Drug Approvals on

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,726 other followers



DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →



Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: